4D Advisors LLC Trims Position in Establishment Labs Holdings Inc. $ESTA

4D Advisors LLC lessened its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 26.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 55,000 shares of the company’s stock after selling 20,000 shares during the period. Establishment Labs accounts for 2.2% of 4D Advisors LLC’s holdings, making the stock its 24th biggest position. 4D Advisors LLC’s holdings in Establishment Labs were worth $4,008,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ESTA. Quarry LP bought a new stake in Establishment Labs during the third quarter valued at about $34,000. Kestra Advisory Services LLC purchased a new stake in shares of Establishment Labs during the fourth quarter worth about $47,000. Osaic Holdings Inc. grew its position in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares in the last quarter. Truist Financial Corp purchased a new stake in shares of Establishment Labs during the fourth quarter worth about $200,000. Finally, PharVision Advisers LLC purchased a new stake in shares of Establishment Labs during the third quarter worth about $203,000. Institutional investors own 72.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 330,000 shares of company stock worth $22,854,538 over the last three months. 9.99% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ESTA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Needham & Company LLC increased their target price on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. BTIG Research increased their target price on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Stephens increased their target price on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Price Performance

Shares of Establishment Labs stock opened at $82.39 on Thursday. The stock has a 50 day moving average of $70.25 and a 200 day moving average of $69.48. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $86.00. The firm has a market cap of $2.42 billion, a PE ratio of -55.29 and a beta of 1.11. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. During the same period in the previous year, the company posted ($0.70) earnings per share. Establishment Labs’s quarterly revenue was up 44.7% on a year-over-year basis. On average, research analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.